pDONR223-PTK2 Citations (3)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-PTK2

Articles
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. Kanojia D, Garg M, Martinez J, M T A, Luty SB, Doan NB, Said JW, Forscher C, Tyner JW, Koeffler HP. J Hematol Oncol. 2017 Nov 13;10(1):173. doi: 10.1186/s13045-017-0540-x. PubMed
Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells. Zhou Z, Li M, Zhang L, Zhao H, Sahin O, Chen J, Zhao JJ, Songyang Z, Yu D. Cancer Res. 2018 May 1;78(9):2248-2261. doi: 10.1158/0008-5472.CAN-17-2726. Epub 2018 Feb 12. PubMed
The intrinsic substrate specificity of the human tyrosine kinome. Yaron-Barir TM, Joughin BA, Huntsman EM, Kerelsky A, Cizin DM, Cohen BM, Regev A, Song J, Vasan N, Lin TY, Orozco JM, Schoenherr C, Sagum C, Bedford MT, Wynn RM, Tso SC, Chuang DT, Li L, Li SS, Creixell P, Krismer K, Takegami M, Lee H, Zhang B, Lu J, Cossentino I, Landry SD, Uduman M, Blenis J, Elemento O, Frame MC, Hornbeck PV, Cantley LC, Turk BE, Yaffe MB, Johnson JL. Nature. 2024 May;629(8014):1174-1181. doi: 10.1038/s41586-024-07407-y. Epub 2024 May 8. PubMed

If you have published an article using this material, please email us at to have your article added to this page.